MOBERG DERMA DISCONTINUES PRECLINICAL DEVELOPMENT PROGRAM FOR A-FIZZ

MOBERG DERMA DISCONTINUES PRECLINICAL DEVELOPMENT PROGRAM FOR A-FIZZ

Moberg Derma AB (OMX: MOB) has decided to discontinue the preclinical
program for the drug candidate for treatment of anal fissures - A-Fizz.
The decision to discontinue was made since the validating preclinical
results did not fulfill the company's criteria.

“It is a disappointment to discontinue the development program but our
product candidates need to meet strict criteria to be approved for
continued investments. Our other development programs progresses
according to plan and our goal of positive cash flow and operating
results 2013 remain unchanged,” said Peter Wolpert, CEO of Moberg Derma.

About this information
Moberg Derma discloses the information provided herein pursuant to the
Securities Markets Act and/or the Financial Instruments Trading Act. The
information was submitted for publication at 16:00 pm (CET) on October
27th, 2011.

For further information, please contact:
Peter Wolpert, President and CEO of Moberg Derma
Telephone: +46 8 522 307 00
Mobile: +46 70- 735 71 35
E-mail: peter.wolpert@mobergderma.se (peter.wolpert@mobergderma.se)

Magnus Persson, IR
Mobile: +46 73-355 26 01
E-mail: magnus.persson@mobergderma.se (magnus.persson@mobergderma.se)